Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 03, 2023, titled "Zydus and Lupin sign licensing agreement for co-marketing of Saroglitazar Mg, a critical treatment for chronic liver diseases in India".
Press Release Nov 03 2023
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a licensing agreement with Lupin for the co-marketing of Saroglitazar Mg, a treatment for chronic liver diseases in India. This innovative drug is approved for conditions such as Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steato Hepatitis, with Zydus continuing to market it under its own brand names. Lupin will market the drug under the brand name LINVAS and will pay Zydus licensing fees and milestone payments based on specific achievements. The partnership aims to enhance access to this critical treatment for patients suffering from these liver conditions in India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 02 2023
- Press Release Oct 31 2023
- Press Release Oct 30 2023
- Press Release Oct 25 2023
- Press Release Oct 20 2023
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Nov 06 2023
- Press Release Nov 07 2023
- Press Release Nov 10 2023
- Press Release Dec 01 2023
- Zydus Lifesciences Limited Press Release Dec 06 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences